Currently out of the existing stock ratings of William Tanner, 9 are a HOLD (20%), 34 are a BUY (75.56%), 2 are a SELL (4.44%).

William Tanner

Work Performance Price Targets & Ratings Chart

Analyst William Tanner, carries an average stock price target met ratio of 56.08% that have a potential upside of 32.46% achieved within 435 days.

William Tanner’s has documented 92 price targets and ratings displayed on 14 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on NVAX, Novavax at 15-Jun-2021.

Wall Street Analyst William Tanner

Analyst best performing recommendations are on SUPN (SUPERNUS PHARMACEUTICALS).
The best stock recommendation documented was for SUPN (SUPERNUS PHARMACEUTICALS) at 4/6/2017. The price target of $31 was fulfilled within 1 day with a profit of $0.8 (2.65%) receiving and performance score of 26.49.

Average potential price target upside

of $27.72 (42.21%) on NVAX (NOVAVAX).
of $23.77 (57.99%) on ARNA (ARENA PHARMACEUTICALS).
of $21.31 (66.26%) on PRTA (PROTHENA PLC).

NVAX Novavax AIMT Aimmune Therapeutics ALKS Alkermes Plc JAZZ Jazz Pharmaceuticals PLC PRTA Prothena plc TXMD TherapeuticsMD AMAG AMAG Pharmaceuticals ARNA Arena Pharmaceuticals CBAY Cymabay Therapeu NLTX Neoleukin Therapeutics RGLS Regulus Therapeutics SGYP Synergy Pharmaceuticals SUPN Supernus Pharmaceuticals XNCR Xencor

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Eric Joseph (JPMORGAN)